ZURA Zura Bio Limited

NASDAQ
$5.57

Zura Bio Limited (ZURA) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.3% since its last earnings release on August 11, 2026.

Zura Bio Limited Missed Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.22)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.64

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Zura Bio Limited

Zura Bio Limited is a clinical-stage biotechnology company advancing primary assets, including ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease and asthma. Zura Bio Limited, formerly known as JATT Acquisition Corp, is headquartered in London, UK.

Sector

Healthcare

Industry

Biotechnology